Chronic infection with Pseudomonas or other bacteria and daily sputum identify 4 clinical phenotypes in bronchiectasis ABSTRACT Bronchiectasis is a heterogeneous disease. This study aimed at identifying discrete groups of patients with different clinical and biological characteristics, and long-term outcomes.
INTRODUCTION
Bronchiectasis is a chronic airway disease characterized by irreversibly damaged and dilated airways leading to recurrent episodes of bronchial sepsis. This results in poor mucus clearance and a vicious cycle of persistent bacterial colonization, airway obstruction, inflammation, and progressive tissue destruction [1] .
The population of patients with bronchiectasis is extremely heterogeneous representing a group of disorders with a wide range of causes and varying clinical, radiological and microbiological features [2] . There are no licensed therapies for bronchiectasis and limited evidence even for widely used treatments such as physiotherapy and long-term macrolide treatment. Recently, a therapeutic approach based on the severity of the disease has been suggested [3] . A step towards a more individualized management of bronchiectasis patients would be the identification of distinct clinical phenotypes using a multidimensional approach that includes parameters available in daily clinical practice.
The majority of therapeutic approaches in bronchiectasis is aimed at the management of chronic bacterial infections, with short and long-term antibiotic courses [3] . It is not known, however, if those patients with chronic bacterial colonization or colonization with Pseudomonas aeruginosa present different clinical characteristics to those patients without. The clinical heterogeneity that characterizes patients with bronchiectasis might reflect different patho-physiological mechanisms, which could be considered potential targets for therapeutic interventions. Cluster analysis or unsupervised machine learning techniques have been successfully used to identify biological and clinical subgroups or "phenotypes" in other respiratory disorders such as asthma and COPD [4] .
In light of the heterogeneity that characterizes patients with bronchiectasis and the need for better directing current management and targeting future treatments, we hypothesized that among these patients there would be discrete groups of subjects with different clinical and biological characteristics.
MATERIALS AND METHODS

Study population
This was a secondary analysis of five databases of prospectively enrolled outpatients with bronchiectasis referred to the bronchiectasis clinics of university teaching hospitals in Monza (Italy), Dundee (UK), Leuven (Belgium), Athens (Greece) and Galway (Ireland). Consecutive patients aged ≥18 years with a diagnosis of bronchiectasis on high-resolution computed tomography (HRCT) scan in stable state were enrolled. Patients with cystic fibrosis or traction bronchiectasis due to pulmonary fibrosis were excluded. A further exclusion criterion for the Athens cohort was either admission to the hospital or use of antibiotics in the prior four weeks and for the Leuven cohort was the presence of active cancer. Collection of selected variables was approved at each individual center by the local ethical committee or institutional review board.
Data collection
At the time of clinical assessment, all patients underwent the same comprehensive diagnostic workup in each site as suggested by the 2010 British Thoracic Society (BTS) guidelines [1] .
Demographics, comorbidities, disease severity, etiology of bronchiectasis, respiratory symptoms, sputum evaluation, radiological, functional and laboratory findings on stable state, quality of life, long-term treatments and outcomes (including exacerbations, hospitalizations and mortality) during a three-year follow-up were uniformly recorded in each database. The Charlson comorbidity index was used to assess comorbidities; this is a sum score of 19 weighted diseases with higher scores denoting increasing burden of comorbidities [5] . The severity of bronchiectasis was evaluated according to both the Bronchiectasis Severity Index (BSI) and FACED score (evaluating FEV1, Age, Ahronic infection with Pseudomonas, radiological Extension and Dyspnea) [6, 7] . Radiological severity of bronchiectasis was assessed using a modified Reiff score, which rates the number of involved lobes (with the lingula considered to be a separate lobe) and the degree of dilatation (range: 1-18) [8] . Patients completed the St. George's Respiratory Questionnaire (SGRQ) as a measure of quality of life [9] . All bacteriology was performed on spontaneous sputum samples as previously described [10] . Murray-Washington criteria for sputum quality was used in all cases, with all samples having less than 10 squamous cells and more than 25 leukocytes per lowpower microscope field. Chronic infection was defined by the isolation of potentially pathogenic bacteria in sputum culture on two or more occasions, at least 3 months apart over a 1-year period [11] . The predominant pathogen was the organism grown most frequently over the study period.
Patients who were unable to provide sputum samples due to absence of a productive cough were classified as not having chronic infection for the purposes of analysis.
Study outcomes
Exacerbations. An exacerbation of bronchiectasis was defined as a clinical diagnosis of exacerbation for which antibiotics were prescribed in the presence of at least one (and usually more than one) of the following symptoms: increasing cough, increasing sputum volume, worsening sputum purulence, worsening dyspnea, increased fatigue/malaise, fever, and haemoptysis [1] . Hospitalization for severe exacerbations. Severe exacerbations were defined according to the BTS guidelines, and unscheduled hospitalizations or emergency department visits for severe bronchiectasis exacerbations or complications were recorded from patient histories and verified using an administrative database that records all regional hospital admissions [1] . Mortality. All-cause mortality for up to 3 years was evaluated.
Statistical analysis
An electronic form was used to collect epidemiological, demographic, clinical, and follow-up variables in the clinical centers participating in the project. Qualitative and quantitative variables were summarized using relative frequencies (percentages) and medians (interquartile ranges, IQR), when appropriate. A chi-squared test and Kruskall-Wallis test were performed to evaluate qualitative and quantitative variables, respectively. A p-value of <0.05 was used to consider a difference statistically significant. A Spearman correlation analysis was performed between all the collected variables; a rho >0.3 was used to select variables to be included in the principal component analysis (PCA). A cutoff eigenvalue of 0.7 was adopted to choose the components, and a factor loading of 0.4 was considered to identify the most important variables to be selected in the cluster analysis [12] . After hierarchical analysis a dendrogram was prepared to visually assess the distribution of the clusters related to the recruited cohort. The number of clusters was decided on the basis of a 20 Gower dissimilarity value. A descriptive and an inferential analysis of the collected variables in between the selected clusters was carried out to detect any statistical differences [13] . All the statistical analyses were performed with the statistical software STATA ® 13 (StataCorp, College Station, TX, USA).
Validation cohort
In order to validate the primary cluster analysis, we recruited an independent population of patients with HRCT confirmed bronchiectasis at Ninewells Hospital, Dundee, UK during 2014. We hypothesized that the clinical clusters identified in the primary study would show differences in neutrophil mediated inflammation. The validation study was conducted as a case control study, with a consecutive cohort of 30 patients recruited in each of the 4 identified phenotype arms (identified by their primary clustering characteristic), see online supplement. Spontaneous sputum samples were obtained and ultracentrifuged at 50,000G for 90mins to obtain supernatant for inflammatory marker measurement as previously described [10] . Clinical evaluation was conducted as described above. Demographics, clinical, functional and radiological status, microbiology, severity of the disease, and long-term antibiotic treatment of the entire study population are presented in Table 1 . A detailed overview of the five cohorts is reported in Table A in the online supplementary material. PCA and cluster analysis, which are reported in the online supplementary material, allowed the identification of four clusters.
RESULTS
Study population
Cluster characteristics
The clinical features of the four clusters are shown in Table 2 . 13 patients were allocated in none of the four clusters because of missing data and excluded by further analysis. The study population was almost equally distributed among the four clusters. Age, sex, body mass index (BMI) and Charlson comorbidity index were not significantly different among the four clusters. On the other hand, the presence and type of chronic infection were the major key factors defining two of the four clusters. Cluster 3 was the largest cluster, including 33% (n= 373) of the study population. No patients within this cluster had chronic infection, but almost all of them had daily sputum and the majority of them were smokers or ex-smokers. Accordingly, this cluster was labelled as "Daily sputum". None of these patients had chronic infection and none had daily sputum. Accordingly, this cluster was labelled as "Dry bronchiectasis".
The etiology of bronchiectasis was identified in 66% (n= 756) of the patients. Excluding idiopathic bronchiectasis, the first three most commonly defined etiologies were post-infective (290, 26%), COPD-related (120, 11%), and CTD-related (89, 8%), (Table 1 ). A detailed distribution of different etiologies among the four clusters is depicted in Table 3 . No clinically and statistically significant differences in terms of bronchiectasis etiology were detected among the four clusters, but for postinfective and COPD-related bronchiectasis.
A significant difference in terms of long-term antibiotic treatment, including macrolide and inhaled antibiotic, was detected among the four clusters ( Table 2 ). More than 50% of the patients in the "Pseudomonas", one-third of the patients in "Other chronic infection and "Daily sputum" clusters were exposed to macrolides. More than one-third of the patients in the "Pseudomonas" cluster were on inhaled antibiotic treatment, while few patients received this treatment in the other clusters.
Quality of life and clinical outcomes during follow up
Quality of life was evaluated in 389 (34%) patients, showing a median (IQR) SGRQ value of 39 (26-58). Significant differences in median values of SGRQ were detected across the four clusters with the worse quality of life for patients in the "Pseudomonas" cluster (Table 4 ).
Significant differences in terms of both exacerbations and hospitalizations due to exacerbations were detected along the four clusters during the one-year follow-up, with the higher rates detected in the "Pseudomonas" and "Other chronic infection" clusters. At oneyear follow up no significant differences in mortality were detected among the different clusters; however, the "Pseudomonas" cluster showed a significant higher mortality rate during the three-year follow up period (Table 4 ).
Biological and clinical validity of the clusters
A total of 120 patients were included in a case-control study, using the major characteristics, namely the presence of Pseudomonas aeruginosa, chronic colonization with other pathogens, daily sputum production without colonization or the absence of these 3 characteristics, see Table 5 . Patients in "Pseudomonas", "Other Chronic infection" and "Daily sputum" clusters were recruited consecutively. As sputum production was less frequent in the "Dry bronchiectasis" cluster, 66 patients were recruited in order to obtain 30 with sputum samples available for analysis. Higher levels of neutrophil elastase, myeloperoxidase and interleukin-1β were found in "Pseudomonas" and "Other chronic infection" clusters, while there were no differences in other cytokines, see Figure 1 .
DISCUSSION
The major finding of our study is the evidence of microbiology, including chronic infections with P. aeruginosa or other pathogens, and the daily presence of sputum production as the major drivers to classify patients with bronchiectasis in four discrete groups. We have further demonstrated that these clusters represent clinical phenotypes because they exhibit differences in terms of not only inflammatory biomarkers on sputum but also quality of life and long-term clinical outcomes.
PCA and cluster analysis have been successfully used in recent years to classify patients with asthma and COPD in discrete groups according to similar combinations of disease characteristics [14] [15] [16] [17] [18] [19] [20] [21] [22] .
No previous studies have used PCA and cluster analysis to identify clinical phenotypes in bronchiectasis. Previous literature defined disease severity through the identification of predictors of mortality and hospital admissions using multivariable analysis [6, 7] . Although scores such as the BSI and the FACED might recognize which patient is globally severe, they do not help physicians in identifying which aspect of patient's management should be addressed firstly in daily clinical practice.
The present analysis, which does not include the derivation cohort of the BSI paper, sought clusters that were not necessarily related to outcomes, but rather patient characteristics providing important new information beyond the available scoring systems.
The presence of chronic infection with Pseudomonas seems to define by itself a specific clinical phenotype of patients with bronchiectasis who share a more relevant inflammatory status, a more severe disease, worse clinical, functional, and radiological characteristics, and worse quality of life and long-term outcomes, in line with previous literature [23] . Two thirds of the patients in the Pseudomonas phenotype were on long-term antibiotic treatment, with half of the patients receiving a macrolide. From a clinical perspective, it is reasonable to assume that patients belonging to this phenotype deserve almost all of the currently available treatment options, including mucus clearance techniques, bronchodilators, inhaled or oral long-term antibiotics, long-term oxygen therapy, embolization and other measurements to control haemoptysis, and vaccinations to prevent exacerbations. However, this clinical phenotype characterized only 16% of the bronchiectasis patients in our cohort, prompting the need to better evaluate characteristics of other phenotypes in order to individualize and optimize management.
Patients with chronic infections other than Pseudomonas recognize a distinct clinical phenotype accounting for 24% of the patients with bronchiectasis. A recent study demonstrated worse outcomes for patients with a chronic infection due to pathogens other than Pseudomonas compared to patients without a chronic infection, but to a lesser extent than those infected with Pseudomonas [6] . Our findings related to the Other chronic infection phenotype, showing intermediate rates of exacerbations, hospitalizations, and mortality in between the Pseudomonas and the Dry bronchiectasis phenotypes, confirming these data. More than one third of the patients in the Other chronic infection phenotype received long-term antibiotic treatment, especially macrolide, with only 5.5% exposed to inhaled antibiotics. There is a paucity of data in literature concerning the evaluation of inhaled antibiotics specifically developed for chronic infections with bacteria other than Pseudomonas, although the percentage of these patients in the bronchiectasis population is not negligible and they do suffer from adverse outcomes.
The largest clinical phenotype in our cohort, the Daily sputum phenotype, was composed by patients who were active smokers, with daily sputum production and without chronic infections. These patients had similar level of disease severity and systemic inflammation, with a similar history of exacerbations, clinical outcomes and chronic antibiotic use in comparison with patients belonging to the Other chronic infection phenotype. These patients would deserve high treatment intensity, although the use of long-term antibiotics cannot be guided by microbiological data obtained by standard methods. However, it would be conceivable that, although with standard method we were not able to identify a chronic infection, new techniques, such as 16S rRNA gene pyrosequencing, could allow the microbiological classification of those patients, broadening potential therapeutic options [24] .
Patients in the Dry bronchiectasis phenotype showed the lowest systemic inflammation level, disease severity, and clinical impact of bronchiectasis, with the best functional status and without any chronic infections. Very few data have been reported in the literature regarding non-clinically significant bronchiectasis and certainly further clinical and translational research is needed to identify early therapeutic targets in order to prevent disease progression.
When we validated our findings in an independent cohort of patients with bronchiectasis, we found that this classification based on the predominant feature of each cluster (chronic infection with Pseudomonas or other bacteria, daily sputum or the absence of daily sputum) is clinically valid with clear differences in lung function, symptoms, and disease severity between groups consistent with the primary analysis. In addition, we found higher levels of neutrophil elastase, myeloperoxidase and interleukin-1β in "Pseudomonas" and "Other chronic infection" clusters, while there were no differences in other cytokines. This is very much consistent with previous published data showing higher levels of neutrophil inflammatory markers in patients with bacterial colonization and higher bacterial loads [10] . This previous literature, together with the present findings, confirms that the bacterial colonization status is the most useful clinical parameter to sub-classify patients.
This study is the first one to apply cluster analysis principles for the identification of clinical phenotypes in bronchiectasis. It represents one of the largest cohorts of patients with bronchiectasis published so far in literature, including patients from five European countries with a three-year followup. The sample size and the multi-center design increase the inference of our findings. One of the strengths of the current analysis is the identification of different phenotypes in bronchiectasis through variables that are usually collected during daily clinical practice. Finally, the presence of differences in sputum biomarkers and quality of life in a validation cohort strengthens the validity of these phenotypes.
One of the limitations of the present study is that, although we merged multiple cohorts obtained in different settings across Europe to ensure representation of different subgroups of patients, all centers were tertiary care ones enrolling a selected population of patients. Further studies should also include cohorts of in/outpatients recruited in both secondary and primary care settings and also collect other important comorbidities not assessed by the Charlson index, such as depression or anxiety. Furthermore, we did not collect the exact date of death and thus we were not able to perform a survival analysis on our cohort. 
